Chronic Hepatitis B – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036
Chronic
Hepatitis B Market Outlook
Thelansis’s “Chronic
Hepatitis B Market Outlook, Epidemiology, Competitive Landscape, and Market
Forecast Report – 2026 To 2036” covers disease overview, epidemiology,
drug utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Chronic Hepatitis B treatment
modalities options for eight major markets (USA, Germany, France, Italy, Spain,
UK, Japan, and China).
Chronic
Hepatitis B Overview
Chronic hepatitis B is a persistent
liver infection caused by the hepatitis B virus, a partially double-stranded
DNA virus that replicates through an RNA intermediate via reverse
transcription. The presence of nuclear covalently closed circular DNA creates
viral persistence and acts as the main barrier to a true cure. Transmission
occurs via perinatal, sexual, or percutaneous routes, with perinatal exposure
carrying the highest risk of chronicity. Contemporary guidelines classify the
disease into distinct stages, shifting away from terms like immune tolerant
toward HBeAg-positive or HBeAg-negative chronic infection and chronic
hepatitis. Diagnoses rely on tracking HBsAg, HBeAg, and HBV DNA levels
alongside elastography to map liver fibrosis. Tenofovir alafenamide, tenofovir
disoproxil fumarate, and entecavir are the preferred first-line nucleos(t)ide
analogues to suppress viral replication durably with a high barrier to
resistance. While pegylated interferon-alfa offers a finite treatment option,
the primary therapeutic goal remains achieving a functional cure, defined by
sustained HBsAg loss. The investigational pipeline has moved past failed capsid
assembly modulators and is now spearheaded by antisense oligonucleotides like
bepirovirsen and targeted small interfering RNAs to suppress viral antigen
production. Long-term management requires strict regular surveillance using
ultrasound and alpha-fetoprotein to screen for hepatocellular carcinoma.
Geography
coverage:
G8 (United
States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights
driven by robust research, including:
- In-depth interviews with leading KOLs
and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based
automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2026–2036)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g.,
drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the most
promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment